Engineering protein-based therapeutics through structural and chemical design

Nature Communications, Год журнала: 2023, Номер 14(1)

Опубликована: Апрель 27, 2023

Protein-based therapeutics have led to new paradigms in disease treatment. Projected be half of the top ten selling drugs 2023, proteins emerged as rivaling and, some cases, superior alternatives historically used small molecule-based medicines. This review chronicles both well-established and emerging design strategies that enabled this paradigm shift by transforming protein-based structures are often prone denaturation, degradation, aggregation vitro vivo into highly effective therapeutics. In particular, we discuss for creating with increased affinity targetability, enhanced stability pharmacokinetics, improved cell permeability, reduced amounts undesired immunogenicity.

Язык: Английский

---

Plant-based biopharmaceutical engineering

Nature Reviews Bioengineering, Год журнала: 2023, Номер 1(6), С. 426 - 439

Опубликована: Март 21, 2023

Язык: Английский

---

The emerging role of nanotechnology in plant genetic engineering

Nature Reviews Bioengineering, Год журнала: 2023, Номер 1(5), С. 314 - 328

Опубликована: Фев. 22, 2023

Язык: Английский

---

Engineered Living Materials for Advanced Diseases Therapy

Advanced Materials, Год журнала: 2023, Номер unknown

Опубликована: Июль 12, 2023

Abstract Natural living materials serving as biotherapeutics exhibit great potential for treating various diseases owing to their immunoactivity, tissue targeting, and other biological activities. In this review, the recent developments in engineered materials, including mammalian cells, bacteria, viruses, fungi, microalgae, plants, active derivatives that are used summarized. Further, future perspectives challenges of such material‐based discussed provide considerations advances biomedical applications.

Язык: Английский

---

Molecular Farming for Immunization: Current Advances and Future Prospects in Plant-Produced Vaccines

Vaccines, Год журнала: 2025, Номер 13(2), С. 191 - 191

Опубликована: Фев. 15, 2025

Using plants as bioreactors, molecular farming has emerged a versatile and sustainable platform for producing recombinant vaccines, therapeutic proteins, industrial enzymes, nutraceuticals. This innovative approach leverages the unique advantages of plants, including scalability, cost-effectiveness, reduced risk contamination with human pathogens. Recent advancements in gene editing, transient expression systems, nanoparticle-based delivery technologies have significantly enhanced efficiency versatility plant-based systems. Particularly vaccine development, demonstrated its potential notable successes such Medicago's Covifenz COVID-19, illustrating capacity platforms to address global health emergencies rapidly. Furthermore, edible vaccines opened new avenues mainly settings low resources where cold chain used conventional logistics is challenge. However, optimization protein yield stability, complexity purification processes, regulatory hurdles are some challenges that still remain. review discusses current status development using operational mechanisms plant platforms, major applications prevention infectious diseases, developments, nanoparticle-mediated cancer vaccines. The discussion will also touch on ethical considerations, framework, future trends respect transformative plant-derived ensuring greater accessibility cost-effectiveness vaccination. field holds great promise disease area and, indeed, personalized medicine biopharmaceuticals near future.

Язык: Английский

---

Recombinant Spider Silk: Promises and Bottlenecks

Frontiers in Bioengineering and Biotechnology, Год журнала: 2022, Номер 10

Опубликована: Март 8, 2022

Spider silk threads have exceptional mechanical properties such as toughness, elasticity and low density, which reach maximum values compared to other fibre materials. They are superior even Kevlar steel. These extraordinary stem from long length specific protein structures. proteins can consist of more than 20,000 amino acids. Polypeptide stretches account for 90% the whole protein, these domains be repeated a hundred times. Each repeat unit has function resulting in final silk. make them attractive innovative material development medical or technical products well cosmetics. However, with livestock breeding spiders it is not possible high volumes due cannibalistic behaviour animals. In order obtain spider (spidroins) on large scale, recombinant production attempted various expression systems plants, bacteria, yeasts, insects, silkworms, mammalian cells For viable large-scale production, cost-effective efficient needed. This review describes different types silk, their structures discusses difficult-to-express host organisms an emphasis plant systems.

Язык: Английский

---

Current status and future prospects in cannabinoid production through in vitro culture and synthetic biology

Biotechnology Advances, Год журнала: 2022, Номер 62, С. 108074 - 108074

Опубликована: Дек. 5, 2022

Язык: Английский

---

Plant glycoengineering for designing next-generation vaccines and therapeutic proteins

Biotechnology Advances, Год журнала: 2023, Номер 67, С. 108197 - 108197

Опубликована: Июнь 13, 2023

Protein glycosylation has a huge impact on biological processes in all domains of life. The type glycan present recombinant glycoprotein depends protein intrinsic features and the repertoire cell used for expression. Glycoengineering approaches are to eliminate unwanted modifications facilitate coordinated expression enzymes or whole metabolic pathways furnish glycans with distinct modifications. formation tailored enables structure-function studies optimization therapeutic proteins different applications. While from natural sources can be vitro glycoengineered using glycosyltransferases chemoenzymatic synthesis, many use genetic engineering involving elimination endogenous genes introduction heterologous cell-based production systems. Plant glycoengineering planta glycoproteins human animal-type that resemble contain novel structures. This review summarizes key achievements plants highlights current developments aiming make more suitable diverse range innovative therapies.

Язык: Английский

---

Self-powered triboelectric-responsive microneedles with controllable release of optogenetically engineered extracellular vesicles for intervertebral disc degeneration repair

Nature Communications, Год журнала: 2024, Номер 15(1)

Опубликована: Июль 9, 2024

Abstract Excessive exercise is an etiological factor of intervertebral disc degeneration (IVDD). Engineered extracellular vesicles (EVs) exhibit excellent therapeutic potential for disease-modifying treatments. Herein, we fabricate self-powered triboelectric-responsive microneedle (MN) assay with the sustainable release optogenetically engineered EVs IVDD repair. Mechanically, promotes cytosolic DNA sensing-mediated inflammatory activation in senescent nucleus pulposus (NP) cells (the master cell population IVD homeostasis maintenance), which accelerates IVDD. TREX1 serves as a crucial nuclease, and disassembly TRAM1-TREX1 complex disrupts subcellular localization TREX1, triggering TREX1-dependent genomic damage during NP senescence. Optogenetically deliver TRAM1 protein into cells, effectively reconstructs elimination function TREX1. Triboelectric nanogenerator (TENG) harvests mechanical energy triggers controllable EVs. Notably, EV-based targeting treatment strategy used IVDD, showing promising clinical degeneration-associated disorders.

Язык: Английский

---

Molecular farming for sustainable production of clinical‐grade antimicrobial peptides

Plant Biotechnology Journal, Год журнала: 2024, Номер 22(8), С. 2282 - 2300

Опубликована: Апрель 29, 2024

Summary Antimicrobial peptides (AMPs) are emerging as next‐generation therapeutics due to their broad‐spectrum activity against drug‐resistant bacterial strains and ability eradicate biofilms, modulate immune responses, exert anti‐inflammatory effects improve disease management. They produced through solid‐phase peptide synthesis or in yeast cells. Molecular farming, i.e. the production of biologics plants, offers a low‐cost, non‐toxic, scalable simple alternative platform produce AMPs at sustainable cost. In this review, we discuss advantages molecular farming for producing clinical‐grade AMPs, advances expression purification systems cost advantage industrial‐scale production. We further review how ‘green’ is filling sustainability gap, streamlining patent regulatory approvals enabling successful clinical translations that demonstrate future potential by farming. Finally, challenges need be addressed fully realize farming‐based AMP therapeutics.

Язык: Английский

---